Prevention of anthrax infection can be achieved with post-exposure prophylaxisantibiotics and vaccination. The US Advisory Committee on Immunization Practices recommended 60 days of antibiotic drug prophylaxis for immediate protection and a 3-dose series of Anthrax Vaccine Adsorbed (AVA) for long-term protection. Postexposure prophylaxis of asymptomatic persons should start as soon as possible after exposure because its effectiveness decreases with delay in implementation. Everyone exposed to aerosolized B. anthracis spores should receive a full 60 days of post-exposure prophylaxis antimicrobial drugs, whether they are unvaccinated, partially vaccinated, or fully vaccinated. Protective measures should also be implemented to prevent the transmission of the disease.[1]
Well-timed and effective postexposure prophylaxis can potentially save thousands of lives. Postexposure prophylaxis of asymptomatic persons should start as soon as possible after exposure because its effectiveness decreases with delay in implementation. Initial symptoms may resemble a common cold, including sore throat, mild fever, myalgia, and malaise. After a few days, the symptoms may progress to severe breathing problems shock, and ultimately death.[2] After exposure to anthrax, it is recommended 60 days of antibiotic drug prophylaxis for immediate protection and a 3-dose series of Anthrax Vaccine Adsorbed (AVA) for long-term protection.[1]
To ensure adequate and continued protection, everyone exposed to aerosolized Bacillus anthracisspores should receive a full 60 days of postexposure prophylaxis antibiotic drugs, whether they are unvaccinated, partially vaccinated, or fully vaccinated.[2]
No safety data are available for levofloxacin use beyond 30 days; thus, oral ciprofloxacin and doxycycline are recommended as first-line antibiotic drugs for postexposure prophylaxis. Alternative antibiotic drugs that might be used for postexposure prophylaxis, if first-line agents are not tolerated or are unavailable, include:[2]
Despite the existence of a vaccine licensed to prevent anthrax, it is not typically available for the general public. It protects against cutaneous and inhalation anthrax. There is evidence of seroconversion after 3 doses of Anthrax Vaccine Adsorbed (AVA). The vaccine should be administered subcutaneously at diagnosis, and 2 and 4 weeks later.[1] AVA is not FDA-approved for postexposure prophylaxis and could be made available under an Investigational New Drug protocol or an Emergency Use Authorization in a declared emergency.
Anthrax vaccine is indicated for the following risk groups of adults:[3]
In order to prevent infection and transmission of the virus, several measures should be implemented, particularly when handling victims of anthrax infection, including:
All possibly contaminated bedding or clothing of infected patients should be isolated in double plastic bags and treated as possible biohazard waste.
If a person is suspected of having died from anthrax, every precaution should be taken to avoid skin contact with the potentially contaminated body. The body should be put in strict quarantine, sealed in an airtight body bag and then cremated. No embalming or autopsy should be attempted without a fully equipped biohazard laboratory and trained, knowledgeable personnel.
Full isolation of the body is important to prevent possible contamination of others. Protective, impermeable clothing and equipment such as rubber gloves, rubber apron, and rubber boots with no perforations should be used when handling the body. No skin, especially if it has any wounds or scratches, should be exposed. Disposable personal protective equipment is preferable, but if not available, decontamination can be achieved by autoclaving.
Anyone working with anthrax in a suspected or confirmed victim should wear respiratory equipment capable of filtering this size of particle or smaller.[6]